Skip to main navigation Skip to search Skip to main content

Incidence and clinical epidemiology of streptococcal septicemia during treatment of acute myeloid leukemia

  • H. van der Lelie
  • , R. J. van Ketel
  • , A. E. von dem Borne
  • , R. H. van Oers
  • , B. L. Thomas
  • , R. Goudsmit

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

The incidence and outcome of streptococcal septicemia was analyzed in 76 consecutive patients with newly diagnosed and relapsed acute myeloid leukemia. They received 215 courses of remission induction or intensive consolidation treatment. There were 31 different episodes of streptococcal septicemia in 27 patients, making these microorganisms the most frequently encountered bacteria in blood cultures. This high incidence coincided with the introduction of selective intestinal decontamination. In 24 episodes (20 patients) there was a fast recovery, but 7 patients developed pulmonary symptoms resulting in death due to respiratory failure in 5 of them. The infections all occurred in the phase of maximum bone marrow suppression 1-3 weeks after the start of the chemotherapy. Streptococcal septicemia was not limited to patients treated with cytosine arabinoside but also occurred in patients treated with other regimens of intensive chemotherapy. In 28 episodes there were no focal signs of infection, but in half there were symptoms of treatment induced gastrointestinal toxicity. The streptococci probably invade through oral and gastrointestinal mucosa damaged by the chemotherapy. Selective decontamination may play a promoting role
Original languageEnglish
Pages (from-to)163-168
JournalScandinavian journal of infectious diseases
Volume23
Issue number2
DOIs
Publication statusPublished - 1991

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Fingerprint

Dive into the research topics of 'Incidence and clinical epidemiology of streptococcal septicemia during treatment of acute myeloid leukemia'. Together they form a unique fingerprint.

Cite this